ALX Oncology Holdings Inc

ALX Oncology Holdings Inc

World Rank (Jan-05-2024)
10,415
Market Cap (Jan-05-2024)
0.717 Billion USD
World Rank (Jul-30-2023)
16,993
Market Cap (Jul-30-2023)
0.243 Billion USD
World Rank (Jan-07-2022)
10,788
Market Cap (Jan-07-2022)
0.777 Billion USD
World Rank (Jan-01-2021)
4,114
Market Cap (Jan-01-2021)
3.199 Billion USD
Headquarters Country
USA
Nasdaq / NYSE Code
ALXO
Market Cap (Mar-08-2026)
0.12
Employee Count
43
Employee Count as of Date
As on 2021
Headquarters City/State
California
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
0 Million USD
Annual Net Income in USD
-83 Million USD
Annual Results for Period Ending
Dec-2021 ending year
Total Assets in USD
380 Million USD
Total Liabilities in USD
17 Million USD
Total Equity in USD
363 Million USD
Balance Sheet for Period Ending
Dec-2021 ending year
Business Sector
Healthcare
Biotechnology
Company Website
ALX ONCOLOGY HOLDINGS INC
Yahoo
Yahoo @ Nasdaq
Company Profile
ALX Oncology is a Clinical Stage Biotechnology company working on Immuno Oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. The company annual revenue is approximately 185.7 million USD. The headquarters is in USA.
IPO Year
2020
Stock Exchange
Nasdaq
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Pharmaceutical Preparations

Share